ProMIS Neurosciences to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
Rhea-AI Summary
ProMIS Neurosciences (Nasdaq: PMN) will participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11-12, 2026 in New York. The company will host a fireside chat at 9:30 AM ET on February 11 and hold investor one-on-one meetings.
A live webcast of the fireside chat will be available via the company Events page at www.promisneurosciences.com and will remain accessible for at least 30 days after the event.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves (e.g., QTTB up 7.09%, AKTX down 4.03%, others near flat), with no clear, synchronized biotech-sector direction mirroring PMN’s 13.17% gain.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Jan 30 | Private placement financing | Positive | +17.9% | Large private placement to fund PMN310 development and extend cash runway. |
| Dec 18 | Clinical trial update | Positive | -5.6% | PRECISE-AD Phase 1b exceeds enrollment target with favorable safety profile. |
| Dec 10 | Scientific publication | Positive | +12.0% | Peer-reviewed data support selective targeting of toxic Aβ oligomers by PMN310. |
| Dec 01 | Biomarker publication | Positive | +3.5% | Publication supports plasma pTau as predictive endpoint aligning with PRECISE-AD design. |
| Dec 01 | Conference participation | Neutral | +3.5% | Investor conference appearance with fireside chat and webcast access. |
Recent news with positive clinical or strategic implications has often seen supportive price reactions, while strong clinical milestones have occasionally faced negative divergence.
Over the past few months, ProMIS has focused on financing, trial execution, and scientific validation. A late-January private placement aimed to fund PMN310 development and extended cash runway, with a +17.95% price reaction. Multiple December publications and trial updates supported the PRECISE-AD Phase 1b program, with mixed reactions ranging from -5.61% to +12%. Prior conference participation on Dec 2, 2025 coincided with a modest gain. Today’s Guggenheim summit participation fits this pattern of ongoing investor outreach alongside clinical progress and recent financing.
Regulatory & Risk Context
The company has an effective Form S-3 shelf registration filed on 2025-09-04, expiring 2028-09-04, which allows it to offer registered securities over time. As of the latest data, the shelf shows no recorded usage events in the provided context.
Market Pulse Summary
This announcement highlights ProMIS’s investor outreach through participation in the Guggenheim Emerging Outlook: Biotech Summit 2026, including a fireside chat on February 11, 2026 and a webcast available for at least 30 days. In recent months, the company secured significant private financing and advanced its PRECISE-AD Phase 1b program. Investors may focus on how ongoing clinical milestones and capital structure developments interact with continued conference visibility and communication efforts.
AI-generated analysis. Not financial advice.
Cambridge, Massachusetts, Feb. 04, 2026 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced the company will be participating in a fireside chat and investor one-on-one meetings at the Guggenheim Emerging Outlook: Biotech Summit 2026 being held from February 11-12th, 2026 in New York, NY.
The fireside chat will be held at 9:30am Eastern Time on Wednesday, February 11th and a live webcast of the presentation may be accessed by visiting the Events page of the Company’s website at www.promisneurosciences.com. The webcast will be available for at least 30 days following the event.
About ProMIS Neurosciences Inc.
ProMIS Neurosciences is a clinical-stage biotechnology company committed to the discovery and development of therapeutic antibodies and vaccines selective for toxic oligomers associated with the development and progression of neurodegenerative and other misfolded protein diseases. The Company’s proprietary target discovery engine, EpiSelect™, has been shown to predict novel targets known as Disease Specific Epitopes (DSEs) on the molecular surface of misfolded proteins that cause neurodegenerative and other misfolded protein diseases, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), multiple system atrophy (MSA), and Parkinson’s Disease (PD). ProMIS has offices in Cambridge, Massachusetts (USA) and Toronto, Ontario (CAN).
About PMN310 and the PRECISE-AD Trial for Alzheimer’s Disease (AD)
PMN310, the Company’s lead product candidate for the treatment of AD, is a humanized monoclonal antibody that has been designed to selectively target only the toxic oligomers, avoiding plaque, thereby potentially reducing, or eliminating amyloid-related imaging abnormalities (ARIA) liability. In addition, because PMN310 may not be limited by off-target binding or side effects, PMN310 could potentially offer an improved efficacy profile over other amyloid-directed antibody therapeutics. PMN310 was granted Fast Track designation by the U.S. Food and Drug Administration in July 2025.
Based on the encouraging results from the Phase 1a trial (NCT06105528) of PMN310, ProMIS initiated PRECISE-AD, a Phase 1b clinical trial in AD patients. PRECISE-AD (NCT06750432) is a randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability and pharmacokinetics (PK) of multiple ascending doses (5, 10, 20 mg/kg) of intravenous PMN310 in patients with Mild Cognitive Impairment due to AD and mild AD (Stage 3 and Stage 4 AD). PRECISE-AD will be the first study to examine the effects of a monoclonal antibody directed solely against AβO on biomarkers associated with AD pathology and clinical outcomes. Safety will be a primary outcome of the study with particular emphasis on assessing whether, as a non-plaque binder, PMN310 may have a reduced risk of ARIA. The study is powered to provide
EpiSelectTM Drug Discovery Engine
Toxic misfolded proteins underlie the pathogenesis of neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and frontotemporal dementia (FTD). Generation of therapeutic antibodies selectively targeting only disease-misfolded protein isoforms, while sparing normal or irrelevant isoforms of the same protein, has not yet been successfully achieved by conventional immunization strategies. ProMIS Neurosciences has developed a computational platform (EpiSelectTM) to identify conformational epitopes that are uniquely exposed on toxic misfolded proteins, which can then be used to generate misfolding-specific antibodies or vaccine formulations. Application of the ProMIS platform produced PMN310, a clinical stage, humanized monoclonal antibody candidate that has been shown to be highly selective for toxic amyloid-beta oligomers (AβO) without significant reactivity with amyloid-beta monomers or fibrils, thereby avoiding target distraction by these more abundant species, and potentially reducing the risk of brain edema and microhemorrhages associated with the targeting of vascular/parenchymal amyloid. Similarly, specific epitopes for alpha-synuclein toxic oligomers/soluble fibrils that drive synucleinopathies, and for pathogenic TDP-43 in ALS and FTD have been identified and lead candidate antibodies generated. The precise conformation of these epitopes has been translated into vaccines inducing an antibody response selective for pathogenic molecular species in preclinical mouse vaccination studies.
For further information:
Visit us at www.promisneurosciences.com
Please submit media inquiries to info@promisneurosciences.com
For Investor Relations, please contact:
Kaytee Bock Zafereo
katherine.bock@promisneurosciences.com
FAQ
When will ProMIS Neurosciences (PMN) present at the Guggenheim Biotech Summit 2026?
How can investors watch the ProMIS (PMN) fireside chat webcast from Guggenheim Biotech Summit?
Will ProMIS Neurosciences (PMN) hold investor meetings at the Guggenheim summit?
What topics will ProMIS (PMN) likely cover in its Guggenheim Biotech Summit presentation?
How long will the ProMIS (PMN) webcast remain available after the Guggenheim summit?
